ACB · Aurora Cannabis Inc.

The thesis

Organigram Global's agreed C$7.80-per-share deal for Aurora Cannabis has replaced Curaleaf's hostile offer as the price to beat. Shareholder votes expected in December 2026, and whether Curaleaf raises before its offer expires on 4 December 2026, settle what Aurora shareholders receive.

The 28 October 2026 note looked for a rival offer or a higher Curaleaf bid to close the gap to Curaleaf's US$5.00 implied value. The rival arrived on 3 November 2026 (Aurora Form 6-K). The shares closed at $5.19 on 5 November 2026, up from $4.15 on 27 October 2026, so much of that case has now been paid.

What remains is narrower: completion of the Organigram deal, the value of its share component, and a possible higher Curaleaf offer. The narrative is accelerating: a second bidder appeared on 3 November 2026, and Curaleaf's chief executive said on the 4 November 2026 earnings call that Curaleaf will "improve our bid substantially" (The Deep Dive).

Bullish and bearish views on Aurora Cannabis Inc.

The bull case on Aurora Cannabis Inc. (ACB), in brief: A definitive agreement now exists. The bear case: Part of the price floats.

Bull case

• A definitive agreement now exists. Aurora's 3 November 2026 release sets three elections per share: C$7.80 cash, 5.8626 Organigram shares, or C$3.75 cash plus 3.0431 Organigram shares. Aurora's board recommends the deal, and it values Aurora's fully diluted equity at about C$561 million.
• The premium is large. The release puts the offer 93% above Aurora's unaffected Toronto Stock Exchange (TSX) close of 10 August 2026. It also puts the offer 21% above the implied value of Curaleaf's bid, using Curaleaf's 20-day volume-weighted average price on 2 November 2026.
• Committed money stands behind the cash. British American Tobacco (BAT) agreed to purchase 141.0 million Organigram shares at C$1.33 for about C$187.5 million. ATB Financial committed and underwrote facilities of up to $210 million, on the terms in the 3 November 2026 release.
• Curaleaf says it will come back. Boris Jordan said on 4 November 2026 that Curaleaf "is going to improve our bid substantially," and The Deep Dive reports he named no price. Curaleaf raised once already, on 5 October 2026, to 0.4013 Curaleaf shares plus US$1.00 cash, with a US$6.00 per-share cap.
• The quarter delivered the guided growth. Aurora reported net revenue of C$86.0 million on 5 November 2026, against C$67.6 million in the prior quarter. International medical revenue reached a record C$61.4 million, up 44% year over year, and Aurora held C$133.0 million of cash and short-term investments with no debt (Aurora Form 6-K).

Bear case

• Part of the price floats. The C$7.80 uses Organigram's 20-day average of about C$1.33 on 2 November 2026, and The Deep Dive reported Organigram shares down about 5% after the announcement. Elections are prorated against caps of 205,826,172 Organigram shares and C$253,638,772 in cash, so an all-cash election may not be filled in full.
• Organigram's own holders must approve. The share issuance and the private placement need a simple majority at Organigram excluding BAT's votes, according to the release. Aurora needs two-thirds of votes cast plus a majority excluding interested holders.
• Curaleaf's raise carries a condition. Jordan called due diligence access an "absolute condition" for a material increase, per The Deep Dive, and he described Aurora as a "bonus" for Curaleaf in that report's paraphrase. Aurora's board still recommends rejecting Curaleaf's bid, and Curaleaf's 3 November 2026 statement says only that its amended offer remains outstanding while it assesses the deal.
• The bidders dispute the gap. Aurora's release states a 21% premium over Curaleaf's offer. Jordan put Organigram's bid at just under 10% above Curaleaf's at the latest close, and he called Organigram's financing contingent, per The Deep Dive.
• Quarterly profit measures slipped. Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) fell to C$14.0 million from C$15.4 million a year earlier, and adjusted gross margin before fair value items fell to 61% from 65%. Aurora reported a C$21.1 million net loss from continuing operations, and company news on 5 November 2026 put the per-share loss at $(0.32) against a $(0.09) estimate.

Price setup

The shares closed at $5.19 on 5 November 2026, 6.8% below the 52-week high of $5.57 and 79.6% higher over three months, on adjusted daily closes. Trading was halted on 3 November 2026 for the announcement, and Benzinga reported the shares up 19.67% at $5.05 that day.

Crowding is visible in momentum. The 14-day relative strength index (RSI) stands at 84.5, against 34.7 on 27 October 2026. Share issuance has not been an observable pressure: Aurora said on 26 October 2026 that its last at-the-market sale was on 18 August 2026.

Organigram's terms are in Canadian dollars and the Nasdaq quote is in US dollars, so the gap between the two moves with the exchange rate and with Organigram's share price. The price now reflects deal terms more than operating results, in this analyst's reading, since the 5 November 2026 report produced no investor call: Aurora cancelled the 12 November 2026 call because of the agreement.

Catalysts, next 30 days

• 4 December 2026: Scheduled expiry of Curaleaf's amended offer, subject to extension. It shows whether Curaleaf raises, extends or lets the offer lapse.
• January 2027: Expected closing of the Organigram deal, subject to the votes, approval of the Supreme Court of British Columbia, TSX approval and German foreign direct investment clearance.

Elapsed catalysts

• December 2026, date not yet set: Special meetings of Aurora and Organigram shareholders, which Aurora's 3 November 2026 release expects. The joint circular is to be mailed "in due course" and will carry the full terms. (passed 3d ago)

What would change the view

The case breaks if the Organigram agreement terminates with no higher offer in its place, or if either company's shareholders vote it down. A refusal of German foreign direct investment clearance would have the same effect, since the release makes it a closing condition.

Curaleaf letting its offer lapse on 4 December 2026 without an increase would remove the contest and leave Organigram's terms as the whole outcome. A sharp fall in Organigram's shares would reduce the value of the share component with no change in terms.

A daily close below $4.15, the 27 October 2026 close from before the agreement, would show the market no longer prices a completed deal. That level replaces the $3.70 invalidation level in the previous note, which predated Organigram's terms. A definitive Curaleaf offer above Organigram's would extend the case past C$7.80.

What it trades with

The shares now link mechanically to Organigram's share price through the share component of the deal, and to Curaleaf's share price through the stock portion of its offer, which is 0.4013 Curaleaf shares per Aurora share. Curaleaf's offer value used a C$14.21 close on 2 October 2026.

While the contest runs, the view here is that deal news will move the shares more than the broader market; a move in the shares that diverges from both bidders' prices with no deal news would undercut that view.